COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics of Epinephrine During Cardiac Arrest

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03036202
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : August 21, 2019
Information provided by (Responsible Party):
Haukeland University Hospital

Brief Summary:
To determine the pharmacokinetics of epinephrine during cardiac arrest.

Condition or disease Intervention/treatment
Cardiac Arrest Drug: Epinephrine

Detailed Description:

The aim of out study is to determine the pharmacokinetics in humans during cardiac arrest, following a single dose of epinephrine. Venous samples will be withdrawn every minute the first five minutes following a single dose.

The aim of the study is to determine T1/2 in a clinical setting and to determine time to peak concentration.

Layout table for study information
Study Type : Observational
Actual Enrollment : 8 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pharmacokinetic Study of Epinephrine During Cardiac Arrest Determining T1/2 and Time to Peak Concentration
Actual Study Start Date : June 26, 2017
Actual Primary Completion Date : July 12, 2018
Actual Study Completion Date : October 12, 2018

Group/Cohort Intervention/treatment
one group
All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
Drug: Epinephrine
This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
Other Name: Adrenaline

Primary Outcome Measures :
  1. Concentration of epinephrine (ng/mL) as a function of time the first five minutes following administration [ Time Frame: Blood samples will be drawn within minutes, and the survivors transported to hospital. The data according to Utstein-style, will also be collected. Blood samples will be analysed within weeks.Total timeframe for the study is estimated to one year. ]
    Blood concentration of epinephrine will be determined the first five minutes following administration. For every minute starting With administration of epinephrine, blood samples will be drawn to determine the concentration (ng/mL). In total, six samples will be drawn. The administered dose (1 mg) will also be related to the patients weight, either estimated, or for those survivors admitted to hospital, measured in the Intensive Care Unit. Further, data according to the Utstein-template will be recorded.However, the primary outcome is to determine the plasma concentrations in every patients the first five minutes.

Biospecimen Retention:   Samples Without DNA
Blood samples with determination of medical concentration in plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with cardiac arrest of an assumed cardiac origin, treated by the Bergen Emergency Medical Service.

Inclusion Criteria:

  • Age 18-85 yrs
  • Witnessed non-traumatic cardiac arrest.
  • Probable cardiac origin
  • Treated by Bergen Emergency Medical Services

Exclusion Criteria:

  • Terminal illness
  • Residents of nursery homes
  • Obvious dead
  • Hypothermic patients
  • Epinephrine administered before arrival of study physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03036202

Layout table for location information
Haukeland University Hospital
Bergen, N, Norway, 5021
Sponsors and Collaborators
Haukeland University Hospital
Layout table for investigator information
Principal Investigator: Baard E Heradstveit, MD, PhD Haukeland University Hospital
Layout table for additonal information
Responsible Party: Haukeland University Hospital Identifier: NCT03036202    
Other Study ID Numbers: 1471-74
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: August 21, 2019
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make individual data available to other researchers. The data will be presented pooled and anonymously

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Haukeland University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents